IDEXX Laboratories shares are trading higher after Barclays maintained an Overweight rating on the stock and raised its price target from $590 to $592.
Portfolio Pulse from Benzinga Newsdesk
Barclays has maintained an Overweight rating on IDEXX Laboratories and raised its price target from $590 to $592, leading to a rise in the company's shares.
November 02, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IDEXX Laboratories' shares are trading higher after Barclays maintained an Overweight rating and raised its price target from $590 to $592.
The news directly pertains to IDEXX Laboratories. Barclays' decision to maintain an Overweight rating and raise the price target is a positive signal, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100